Vermillion, Inc. (VRML): Price and Financial Metrics
VRML Price/Volume Stats
| Current price | $4.00 | 52-week high | $5.78 |
| Prev. close | $4.33 | 52-week low | $0.35 |
| Day low | $3.65 | Volume | 1,319,300 |
| Day high | $4.25 | Avg. volume | 440,144 |
| 50-day MA | $2.14 | Dividend yield | N/A |
| 200-day MA | $1.07 | Market Cap | 389.51M |
VRML Stock Price Chart Interactive Chart >
Latest VRML News From Around the Web
Below are the latest news stories about Vermillion Inc that investors may wish to consider to help them evaluate VRML as an investment opportunity.
Vermillion changes its name to Aspira Women’s Health Inc.Vermillion (VRML) has changed its name to Aspira Women’s Health, effective today and will trade on the Nasdaq Stock Market under the new ticker symbol “AWH” and a new CUSIP (04537Y109), effective June 12. Valerie Palmieri, President, and Chief Executive Officer of Aspira Women’s Health said, “Our new company name... |
Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Women’s Health Inc.Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change to Aspira Women’s Health Inc effective today, June 11, 2020. The company’s common stock will trade on the Nasdaq Stock Market under the new ticker symbol “AWH” effective June 12, 2020. |
Vermillion set to roll out COVID-19 test and new cancer biomarkersVermillion (VRML) subsidiary ASPIRA Labs has finished validating Roche's Elecsys Anti-SARS-CoV-2 antibody blood test in addition to several new oncology biomarkers.The Roche assay demonstrated 100.0% sensitivity and 99.8% specificity.ASPIRA plans to offer the assay and additional pelvic mass risk assessment biomarkers by month-end in conjunction with its proprietary OVA1 plus... |
Why Vermillion's Stock Is Trading Higher TodayVermillion, Inc. (NASDAQ: VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including coronavirus antibody testings.The company is also expected to join the Russell 3000 Index on June 29.Vermillion is a diagnostic service and bio-analytic solutions provider company. It is engaged in the business of developing and commercializing diagnostic tests for the gynecologic disease. The company's products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Geographically all the operations are functioned from the region of U.S.Vermil... |
Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment BiomarkersAUSTIN, Texas, June 10, 2020 -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its. |
VRML Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 700.00% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 170.00% |
| 2018 | -84.46% |
Continue Researching VRML
Want to do more research on Vermillion Inc's stock and its price? Try the links below:Vermillion Inc (VRML) Stock Price | Nasdaq
Vermillion Inc (VRML) Stock Quote, History and News - Yahoo Finance
Vermillion Inc (VRML) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...